Early Detection Research Network

CDKN1A

Aliases:
This biomarker is also known as:
  • CDKN1A,
  • wild-type p53-activated fragment 1,
  • p21,
  • P21,
  • MDA-6,
  • CDK-interaction protein 1,
  • cyclin-dependent kinase inhibitor 1A (p21, Cip1),
  • p21Cip1/Waf1,
  • MDA6,
  • CDKN1,
  • cyclin-dependent kinase inhibitor 1,
  • WAF1,
  • DNA synthesis inhibitor,
  • melanoma differentiation associated protein 6,
  • p21CIP1,
  • SDI1,
  • CDK-interacting protein 1,
  • CIP1,
  • CAP20,
  • Melanoma differentiation-associated protein 6,
  • PIC1,

Description…

From NCBI Gene: This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-cyclin-dependent kinase2 or -cyclin-dependent kinase4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen, a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of cyclin-dependent kinase2, and may be instrumental in the execution of apoptosis following caspase activation. Mice that lack this gene have the ability to regenerate damaged or missing tissue. Multiple alternatively spliced variants have been found for this gene. [provided by RefSeq, Sep 2015]

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
Type: Gene
HGNC Name: CDKN1A

The following organs have data associated with this biomarker…

Attributes

Phase: One
QA State: Under Review

Overview

No additional prostate data available.

Performance Comment

19 common probe sets (15 unique genes) were used to develop a PAM-based classifier, which had an average accuracy of 87% when it was tested on 47 independent tumor-adjacent stroma samples. The 15 genes represented in the classifier are: GADD45B, CDKN1A, NLRP1, ERBB3, FMO5, KIAA0746///SERINC2, AMFR, DPP4, PGC, YWHAE, EHF, TF, TNFSF10, EIF5A, TGM4. This is the first general tumor microenvironment-based prognostic classifier. Tumor-adjacent prostate cancer stroma contains numerous changes in gene expression at the time of diagnosis that correlate with the chance of relapse following prostatectomy. These results indicate that the prostate cancer microenvironment exhibits reproducible changes useful for predicting outcomes for patients.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.